Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial

Publication date: Available online 31 October 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Dag Hofsø, Farhat Fatima, Heidi Borgeraas, Kåre Inge Birkeland, Hanne Løvdal Gulseth, Jens Kristoffer Hertel, Line Kristin Johnson, Morten Lindberg, Njord Nordstrand, Milada Cvancarova Småstuen, Darko Stefanovski, Marius Svanevik, Tone Gretland Valderhaug, Rune Sandbu, Jøran HjelmesæthSummaryBackgroundFor patients with obesity and type 2 diabetes, weight loss improves insulin sensitivity and β-cell function, and can induce remission of diabetes. The comparative efficacy of various bariatric procedures for the remission of type 2 diabetes has not been fully elucidated. We aimed to compare the effects of the two most common bariatric procedures, gastric bypass and sleeve gastrectomy, on remission of diabetes and β-cell function.MethodsWe conducted a single-centre, triple-blind, randomised trial at Vestfold Hospital Trust (Tønsberg, Norway), in which patients (aged ≥18 years) with type 2 diabetes and obesity were randomly assigned (1:1) to receive gastric bypass or sleeve gastrectomy (the Oseberg study). Randomisation was performed with a computerised random number generator and a block size of 10. Treatment allocation was masked from participants, study personnel, and outcome assessors and was concealed with sealed opaque envelopes. Surgeons used identical skin incisions during both surgeries and were not involved in patient follow-up. The primary clinical outcome ...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research